ABVC BioPharma (NASDAQ:ABVC) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPS

by · The Markets Daily

ABVC BioPharma (NASDAQ:ABVC – Get Free Report) released its earnings results on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.36, FiscalAI reports.

ABVC BioPharma Price Performance

Shares of ABVC BioPharma stock traded down $0.03 during trading hours on Tuesday, reaching $0.99. The company’s stock had a trading volume of 34,952 shares, compared to its average volume of 100,511. The firm has a 50 day moving average price of $1.01 and a 200-day moving average price of $1.23. ABVC BioPharma has a one year low of $0.71 and a one year high of $3.06. The stock has a market cap of $26.42 million, a P/E ratio of -3.30 and a beta of 0.47.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Stock Report on ABVC BioPharma

About ABVC BioPharma

(Get Free Report)

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners. ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.

Featured Stories